{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:42:07Z","timestamp":1782254527113,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To prospectively investigate the feasibility, toxicity, and preliminary clinical outcomes of magnetic resonance (MR)-guided stereotactic total ablative radiotherapy (MRgSTAR) for simultaneous treatment of the prostate and pelvic bone metastases in patients with synchronous oligometastatic prostate cancer (OMPC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included patients with histologically confirmed synchronous OMPC, defined as \u2264 5 lymph node or pelvic bone metastases identified via prostate-specific membrane antigen positron emission tomography (PSMA-PET). Real-time adaptive MRgSTAR was delivered using a 1.5T MR-integrated linear accelerator (MR-LINAC) in five fractions, administered twice weekly, targeting the prostate (33.5\u201340 Gy) and nodal\/bone metastases (36.5\u201340 Gy) simultaneously. Androgen-deprivation therapy (ADT) was initiated prior to MRgSTAR, with the addition of androgen receptor pathway inhibitor (ARPI) at the physician\u2019s discretion. Adverse events (AEs) were assessed using the Common Terminology Criteria for AEs v5.0, and tumor response was evaluated per the Response Evaluation Criteria in Solid Tumors v1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan\u2013Meier method, with log-rank tests used to explore clinical factors associated with survival outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-three patients underwent MRgSTAR, with a median follow-up of 36.5 months (range: 15.4\u201357.6 months). ADT combined with ARPI therapy was administered in 22 patients (52%). All patients completed the five-fraction regimen. Biochemical progression occurred in three patients, of whom two had out-of-field metastases and one had local progression as per follow-up PSMA-PET. The estimated 3-year OS and PFS rates were 100% and 95.2% (95% confidence interval: 89.0%\u2013100%), respectively. No clinical factors, including ARPI use, significantly correlated with survival outcomes. No radiotherapy-related AEs of grade \u2265 3 were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MRgSTAR demonstrates promising early survival outcomes and a favorable toxicity profile in synchronous OMPC, warranting further investigation to confirm its therapeutic role.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1607610","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:56:01Z","timestamp":1751536561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Stereotactic total ablative radiotherapy with MR-LINAC for synchronous oligometastatic prostate cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Darren MC.","family":"Poon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oi Lei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin Ting","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin Yin","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu Ki","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.02.003","article-title":"Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary radical treatment: A systematic review","volume":"4","author":"Farolfi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 advanced prostate cancer consensus conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737140.2025.2509760","article-title":"Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer","author":"Ingrosso","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.023","article-title":"Patient-reported quality of life in patients with primary metastatic prostate cancer treated with androgen deprivation therapy with and without concurrent radiation therapy to the prostate in a prospective randomised clinical trial; data from the HORRAD trial","volume":"79","author":"Boeve","year":"2021","journal-title":"Eur Urol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur Urol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.12.040","article-title":"STAMPEDE: is radiation therapy to the primary a new standard of care in men with metastatic prostate cancer","volume":"104","author":"Choudhury","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/59\/21\/R349","article-title":"MR guidance in radiotherapy","volume":"59","author":"Lagendijk","year":"2014","journal-title":"Phys Med Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2019.04.001","article-title":"Adaptive radiotherapy: The Elekta Unity MR-linac concept","volume":"18","author":"Winkel","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-021-01352-w","article-title":"Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes","volume":"126","author":"Mazzola","year":"2021","journal-title":"Radiol Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00066-021-01834-w","article-title":"Stereotactic body radiotherapy of lymph node metastases under MR-guidance: First clinical results and patient-reported outcomes","volume":"198","author":"Weykamp","year":"2022","journal-title":"Strahlenther Onkol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04675-7","article-title":"MR-guided prostate SBRT in prostate cancer patients with low-volume metastatic disease","volume":"41","author":"Moningi","year":"2023","journal-title":"World J Urol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.05.034","article-title":"Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO)","volume":"138","author":"D\u2019Angelillo","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.05.034","article-title":"Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases","volume":"114","author":"Siva","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.5603\/RPOR.a2021.0077","article-title":"Radiation therapy with curative intention in men with de novo metastatic prostate carcinoma: shoot\u2019em all","volume":"26","author":"Montero","year":"2021","journal-title":"Rep Pract Oncol Radiother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"17471","DOI":"10.1038\/s41598-020-74562-3","article-title":"Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer","volume":"10","author":"Reverberi","year":"2020","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.06.018","article-title":"Clinical outcomes of combined prostate- and metastasis-directed radiation therapy for the treatment of de novo oligometastatic prostate cancer","volume":"5","author":"Imber","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20190353","article-title":"Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases","volume":"93","author":"Deantoni","year":"2020","journal-title":"Br J Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-024-01782-2","article-title":"Image-guided moderately hypofractionated radiotherapy for localized prostate cancer: a multicentric retrospective study (IPOPROMISE)","volume":"129","author":"Ingrosso","year":"2024","journal-title":"Radiol Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1607610\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:56:02Z","timestamp":1751536562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1607610\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1607610"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1607610","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"article-number":"1607610"}}